title

Project Oncology®

ReachMD

0
Followers
0
Plays
Project Oncology®

Project Oncology®

ReachMD

0
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

Project Oncology® presents a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. This series provides cutting-edge updates on cancer biology, diagnosis, and multidisciplinary management, as well as evidence-based recommendations to achieve optimal patient outcomes.

Latest Episodes

HIPEC: A Novel Treatment for Advanced Abdominal Cancers

Host: John J. Russell, MD Guest: Nabil Wasif, MD Image: Mayo Foundation For Medical Education and Research. All Rights Reserved. Short for hypothermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the benefits and drawbacks of HIPEC. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

-1 sJAN 23
Comments
HIPEC: A Novel Treatment for Advanced Abdominal Cancers

Best Practices for Curative-Intent Concurrent Chemoradiation Therapy in Unresectable Stage III NSCLC

Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19

-1 sJAN 13
Comments
Best Practices for Curative-Intent Concurrent Chemoradiation Therapy in Unresectable Stage III NSCLC

Multidisciplinary Perspectives on Managing Patients with Unresectable Stage III NSCLC

Host: Jennifer Caudle, DO Guest: Alexander Whitley, MD Guest: Alejandro Calvo, MD Guest: Kim Rohan, MS APN, AOCN At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer. US-32360 Last Updated 12/19

-1 sJAN 13
Comments
Multidisciplinary Perspectives on Managing Patients with Unresectable Stage III NSCLC

Perspectives on Proton Beam Therapy: Benefits, Challenges, & Results

Host: Jennifer Caudle, DO Guest: Robert Foote, MD Guest: Anita Mahajan, MD Image: Mayo Foundation For Medical Education and Research. All Rights Reserved. When compared to traditional x-ray radiation therapy, proton beam therapy is a more targeted form of therapy that offers a lower dose of radiation to impacted organs and fewer side effects and complications, which explains why its being recommended as a treatment option more and more. But what are some of the other benefits—and challenges—of proton beam therapy? That’s what Drs. Anita Mahajan and Robert Foote are here to discuss. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

-1 sJAN 2
Comments
Perspectives on Proton Beam Therapy: Benefits, Challenges, & Results

New Treatment Approaches for Historically Inoperable Pancreatic Cancers

Host: William Mencia, MD, FACEHP, CHCP Guest: Chee-Chee Stucky, MD Image: Mayo Foundation For Medical Education and Research. All Rights Reserved. About a third of the 55,000 Americans diagnosed with pancreatic cancer each year were considered inoperable due to the tumor growing outside the pancreas. But now, that conventional wisdom is being challenged with the release of data from a recent study, as Dr. Chee-Chee Stucky, a surgical oncologist from Mayo Clinic, explains. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

-1 s2019 DEC 31
Comments
New Treatment Approaches for Historically Inoperable Pancreatic Cancers

Updates From the PACIFIC Study & Its Impact on the Unresectable Stage III NSCLC Treatment Landscape

Host: Jennifer Caudle, DO Guest: Timothy Kruser, MD Recorded live at the 2019 ASTRO Annual Meeting in Chicago, Illinois, tune in to hear Dr. Timothy Kruser share key updates from the PACIFIC study. IMFINZI (durvalumab) is indicated for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following cCRT. Select Safety Information: Serious, potentially fatal risks were seen with IMFINZI in the PACIFIC trial. The most frequent serious adverse events (occurring in greater than or equal to 2% of patients) were pneumonitis or radiation pneumonitis and pneumonia. Immune-mediated adverse reactions, including immune-mediated pneumonitis, hepatitis, colitis or diarrhea, endocrinopathies (including thyroid disorders, adrenal insufficiency, type 1 diabetes, and hypophysitis), nephritis, dermatologic reactions, and other immune-mediated adverse reactions; infection; and infusion-related reactions were reported in patients receiving IMFINZI in the PACIFIC t...

-1 s2019 DEC 10
Comments
Updates From the PACIFIC Study & Its Impact on the Unresectable Stage III NSCLC Treatment Landscape

Advancing Care in Gastrointestinal Cancers

Host: Paul Oberstein, MD Guest: Eileen M. O'Reilly, MD As new evidence continues to be published and presented at scientific conferences, oncologists are finding it more difficult to stay on top of new information. That’s why Drs. Eileen O'Reilly and Paul Oberstein are here to review selected abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting… but the catch is that they only have 3 minutes to cover each update in this clinical countdown discussion. Can they beat the clock?

-1 s2019 NOV 29
Comments
Advancing Care in Gastrointestinal Cancers

A Look at Current & Potential Therapies for High Grade Glioma

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. 2019 Tocagen. All rights reserved. VV-REG-003123 10/19

-1 s2019 NOV 18
Comments
A Look at Current & Potential Therapies for High Grade Glioma

The BiTE Immuno-Oncology Platform & Emerging Targets in Oncology

Host: Matt Birnholz, MD Guest: Ajai Chari, MD Amgen's [BiTE] technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Binrholz is joined by Dr. Ajai Chari. USA-OCF-80679

-1 s2019 OCT 25
Comments
The BiTE Immuno-Oncology Platform & Emerging Targets in Oncology

Improving Outcomes in HER2+ Early Breast Cancer

Guest: Charles Geyer, MD With clinical trials showing improvements over the current standard of care for HER2+ early breast cancer, incorporating new data and medications into this treatment paradigm is becoming a top priority. Listen in as Dr. Charles Geyer reviews the emerging approaches to adjuvant therapy in patients with HER2+ early breast cancer.

-1 s2019 SEP 14
Comments
Improving Outcomes in HER2+ Early Breast Cancer

Latest Episodes

HIPEC: A Novel Treatment for Advanced Abdominal Cancers

Host: John J. Russell, MD Guest: Nabil Wasif, MD Image: Mayo Foundation For Medical Education and Research. All Rights Reserved. Short for hypothermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the benefits and drawbacks of HIPEC. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

-1 sJAN 23
Comments
HIPEC: A Novel Treatment for Advanced Abdominal Cancers

Best Practices for Curative-Intent Concurrent Chemoradiation Therapy in Unresectable Stage III NSCLC

Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19

-1 sJAN 13
Comments
Best Practices for Curative-Intent Concurrent Chemoradiation Therapy in Unresectable Stage III NSCLC

Multidisciplinary Perspectives on Managing Patients with Unresectable Stage III NSCLC

Host: Jennifer Caudle, DO Guest: Alexander Whitley, MD Guest: Alejandro Calvo, MD Guest: Kim Rohan, MS APN, AOCN At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer. US-32360 Last Updated 12/19

-1 sJAN 13
Comments
Multidisciplinary Perspectives on Managing Patients with Unresectable Stage III NSCLC

Perspectives on Proton Beam Therapy: Benefits, Challenges, & Results

Host: Jennifer Caudle, DO Guest: Robert Foote, MD Guest: Anita Mahajan, MD Image: Mayo Foundation For Medical Education and Research. All Rights Reserved. When compared to traditional x-ray radiation therapy, proton beam therapy is a more targeted form of therapy that offers a lower dose of radiation to impacted organs and fewer side effects and complications, which explains why its being recommended as a treatment option more and more. But what are some of the other benefits—and challenges—of proton beam therapy? That’s what Drs. Anita Mahajan and Robert Foote are here to discuss. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

-1 sJAN 2
Comments
Perspectives on Proton Beam Therapy: Benefits, Challenges, & Results

New Treatment Approaches for Historically Inoperable Pancreatic Cancers

Host: William Mencia, MD, FACEHP, CHCP Guest: Chee-Chee Stucky, MD Image: Mayo Foundation For Medical Education and Research. All Rights Reserved. About a third of the 55,000 Americans diagnosed with pancreatic cancer each year were considered inoperable due to the tumor growing outside the pancreas. But now, that conventional wisdom is being challenged with the release of data from a recent study, as Dr. Chee-Chee Stucky, a surgical oncologist from Mayo Clinic, explains. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

-1 s2019 DEC 31
Comments
New Treatment Approaches for Historically Inoperable Pancreatic Cancers

Updates From the PACIFIC Study & Its Impact on the Unresectable Stage III NSCLC Treatment Landscape

Host: Jennifer Caudle, DO Guest: Timothy Kruser, MD Recorded live at the 2019 ASTRO Annual Meeting in Chicago, Illinois, tune in to hear Dr. Timothy Kruser share key updates from the PACIFIC study. IMFINZI (durvalumab) is indicated for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following cCRT. Select Safety Information: Serious, potentially fatal risks were seen with IMFINZI in the PACIFIC trial. The most frequent serious adverse events (occurring in greater than or equal to 2% of patients) were pneumonitis or radiation pneumonitis and pneumonia. Immune-mediated adverse reactions, including immune-mediated pneumonitis, hepatitis, colitis or diarrhea, endocrinopathies (including thyroid disorders, adrenal insufficiency, type 1 diabetes, and hypophysitis), nephritis, dermatologic reactions, and other immune-mediated adverse reactions; infection; and infusion-related reactions were reported in patients receiving IMFINZI in the PACIFIC t...

-1 s2019 DEC 10
Comments
Updates From the PACIFIC Study & Its Impact on the Unresectable Stage III NSCLC Treatment Landscape

Advancing Care in Gastrointestinal Cancers

Host: Paul Oberstein, MD Guest: Eileen M. O'Reilly, MD As new evidence continues to be published and presented at scientific conferences, oncologists are finding it more difficult to stay on top of new information. That’s why Drs. Eileen O'Reilly and Paul Oberstein are here to review selected abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting… but the catch is that they only have 3 minutes to cover each update in this clinical countdown discussion. Can they beat the clock?

-1 s2019 NOV 29
Comments
Advancing Care in Gastrointestinal Cancers

A Look at Current & Potential Therapies for High Grade Glioma

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. 2019 Tocagen. All rights reserved. VV-REG-003123 10/19

-1 s2019 NOV 18
Comments
A Look at Current & Potential Therapies for High Grade Glioma

The BiTE Immuno-Oncology Platform & Emerging Targets in Oncology

Host: Matt Birnholz, MD Guest: Ajai Chari, MD Amgen's [BiTE] technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Binrholz is joined by Dr. Ajai Chari. USA-OCF-80679

-1 s2019 OCT 25
Comments
The BiTE Immuno-Oncology Platform & Emerging Targets in Oncology

Improving Outcomes in HER2+ Early Breast Cancer

Guest: Charles Geyer, MD With clinical trials showing improvements over the current standard of care for HER2+ early breast cancer, incorporating new data and medications into this treatment paradigm is becoming a top priority. Listen in as Dr. Charles Geyer reviews the emerging approaches to adjuvant therapy in patients with HER2+ early breast cancer.

-1 s2019 SEP 14
Comments
Improving Outcomes in HER2+ Early Breast Cancer
hmly
himalayaプレミアムへようこそ聴き放題のオーディオブックをお楽しみください。